Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — ITUS — Investor Presentation (June 2017)
25 slides from Anixa Biosciences's investor presentation, Jun 2, 2017
Slide 1: ITUS Corporation
ITUS CORPORATION Nasdaq: ITUS May 2017
Slide 2: Forward Looking Statement
ITUS FORWARD LOOKING STATEMENT This presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements are not statements of historical facts, but
Slide 3: Benefits of Early Detection
ITUS BENEFITS OF EARLY DETECTION 5 Year Survival Rates 100 99 92- 100 75 50 25 Breast Cancer Cervical Cancer i ° Ovarian Cancer Prostate Cancer Colon Cancer Late Stage Diagnosis ™@ Early Stage Diagnosis
Slide 4: Non-Invasive Cancer Testing (Liquid Biopsy)
ITUS NON-INVASIVE CANCER TESTING (LIQUID BIOPSY) $1.1 Billion $1.7 Billion $5.0 Billion -9 Billion Predisposition Testing Therapy Treatment Recurrence Selection Monitoring Testing Sources: Piper Jaffray - The 2015 Liquid Biopsy Report 4 Modor — Ss)
Slide 5: Effective Cancer Diagnostic
EFFECTIVE CANCER DIAGNOSTIC High Sensitivity (Detect early stage) 7 High Specificity Reliable (Low False Positives) Non-invasive, low pain, convenient Easy Low risk of complications Cost Affordable (Reimb bl Effective ordable (Reimbursable)
Slide 6: Problems with Cancer Screening Tests
ITUS PROBLEMS WITH CANCER SCREENING TESTS Low Dose CT PSA Mammogram | Colonoscopy (Lung Cancer) | (ProstateCancer)| (Breast Cancer) | (Colon Cancer) Reliable x xX 4 Vv Easy xX vY x x cel x V x x
Slide 7: ITUS
ITUS
Slide 8: Immune Response to Cancer
ITUS IMMUNE RESPONSE TO CANCER ¢ It is well known that malignancies induce a | ieee | | __vmenoores | strong immune response The Tumor Micro-Environment consists of cancer cells as well as immune cells including T-cells, NK cells, B- cells, Monocytes, Dendritic cells, etc. The interaction between ca
Slide 9: Myeloid Derived Suppressor Cells - MDSC's
ITUS MYELOID DERIVED SUPPRESSOR CELLS - MDSC’S ¢ Myeloid Cells emanate from progenitor stem cells in bone marrow and include cells such as Monocytes, Macrophages, Eosinophils, Neutrophils ¢ MDSCs are immature Myeloid Cells whose development is inhibited by the cancer and which are corrupted to suppr
Slide 10: Cchek Cancer Detection Technology
ITUS CG cancer DETECTION TECHNOLOGY * By using proprietary protocols, ITUS has been able to detect diagnostic subsets of MDSCs and other immune cells in the peripheral blood of cancer patients e ITUS has detected MDSCs at various stages and types of cancers, including stage 1 * By using subsets of M
Slide 11: Assay Development
ITUS & Assay Development Fluorescent Cell Surface Markers Flow Cytometry (Proprietary Formula) Single Tube Blood Separation via Density Whole Blood Centrifugation Cell Counting Lazer Impedance Sorting Biomarker Detection g ae 5 $e MDSCs | | . 5 1 g é, + é Be 3 ‘ 4 é Other Immune Cell Healthy 3 a 8 a
Slide 12: Clinical Validation
ITUS CLINICAL VALIDATION Hf Sensitivity Specificity li Cchek-Sensitivity I Cchek-Specificity 91% 94% — 100% 93% 5% 75% pe 50% 35% 25% 0% LDCT Mammogram Cchek Cchek results tested in an unblinded manner and based on 54 samples from patients with 14 types and varying stages of neerandiaa : : . f . a
Slide 13: Worldwide Cancer Incidences
ITUS WORLDWIDE CANCER INCIDENCES L Breast 12% Colon 10% Prostate 8%
Slide 14: Cancer Types Validated
ITUS CANCER TYPES VALIDATED | Leiomy- Lung ‘Sarcoma » oeearcon es - - <4 t Total Cancers >. 341 | Breast Appendiceal Melanoma Uterine/Endo. Osteosarcoma
Slide 15: Potential Markets
ITUS ‘© POTENTIAL MARKETS Screening Confirmatory Testing Treatment Monitoring Effectiveness of chemotherapy, radiation, and other Testing for asymptomatic adults Verification for Mammogram, PSA, Chest X-ray treatments Recurrence Testing Allows frequent recurrence monitoring
Slide 16: Breast Cancer
BREAST CANCER Screening Confirm. Testing Biopsy Diagnosis @ ER Fe) 40 million 44 million 1.3 million 165,000 1.1 million unnecessary needle biopsies
Slide 17: Breast Cancer
BREAST CANCER Screening Confirm. Testing Biopsy Diagnosis i> '5>)> = 40 million 44 million 200,000 165,000 1.1 Million fewer needle biopsies
Slide 18: Prostate Cancer
PROSTATE CANCER Screening Biopsy Diagnosis ? x la DRE (Digital Rectal Exam) 30 million 1.0 million 161,360 840,0 unnecessary prostate biopsies PSA (Prostate-Specific Antigen)
Slide 19: Prostate Cancer
PROSTATE CANCER Screening Confirm. Testing Biopsy Diagnosis DRE (Digital Rectal Exam) 30 million 300,000 161,360 hi 70 PSA (Prostate-Specific Antigen) 000 fewer prostate biopsies
Slide 20: Collaborations
ITUS COLLABORATIONS MD Anderson etc] UNIVERSITY OF Cancer 7 4) PENNSYLVANIA Networ k PES Cancer Center A Wirtua @ comspeayr ee
Slide 21: Scientific Advisors
ITUS SCIENTIFIC ADVISORS Dr. Arnold Baskies | American Chairman - American Cancer Society F Society° i. oo. THE Dr. Dimitry Gabrilovich WISTAR Renowned expert Tumor Derived Myeloid Cells INSTITUTE Dr. Michael Shepard FOUR et
Slide 22: ITUS - Executive Management
ITUS ITUS - EXECUTIVE MANAGEMENT Amit Kumar, Ph.D - Executive Chairman, Inventor of Cchek™ A.B. Occidental College, Ph. D. Caltech, Post-Doc. Harvard Former CEO - CombiMatrix Corporation Frequent board member and advisor to investment funds, venture capital firms, and Fortune 500 companies. Robert B
Slide 23: Cchek Next Steps
ITUS Cnexr STEPS Refine Protocols Refine Artificial Intelligence Cross-reactivity and Benign Conditions Announce First Commercial Product Pre-Clinical Trial Regulatory Standardization Clinical Trial
Slide 24: ITUS - Financial Highlights
ITUS ITUS - FINANCIAL HIGHLIGHTS (as of May 26, 2017) Cash on Hand >$8.1M Monthly Burn >$350K Debt >$3.0M Market Cap >$14M 52 Week Range »$.86 - $6.82 Shares Outstanding >15.1M Non-Affiliated Float >14.4M
Slide 25: ITUS Corporation
ITUS CORPORATION